Anti-apoptotic effect of Shudipingchan granule in the substantia nigra of rat models of Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Anti-apoptotic effect of Shudipingchan granule in the substantia nigra of rat models of Parkinson's disease.

Anti-apoptotic effect of Shudipingchan granule in the substantia nigra of rat models of Parkinson's disease.

http://www.wikidata.org/entity/Q37425231

about

Anti-apoptotic effect of Shudipingchan granule in the substantia nigra of rat models of Parkinson's disease.

http://www.wikidata.org/entity/Q37425231

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-apoptotic effect of Shudi ...... models of Parkinson's disease.

@en

Anti-apoptotic effect of Shudi ...... models of Parkinson's disease.

@nl

type

label

Anti-apoptotic effect of Shudi ...... models of Parkinson's disease.

@en

Anti-apoptotic effect of Shudi ...... models of Parkinson's disease.

@nl

prefLabel

Anti-apoptotic effect of Shudi ...... models of Parkinson's disease.

@en

Anti-apoptotic effect of Shudi ...... models of Parkinson's disease.

@nl

P1433

Q37425231-83ED50B1-DE35-4B75-8B70-079ED4EC232D

P1476

Q37425231-ED66B567-AAB0-4F22-841F-7BFB71999507

P2093

Q37425231-17583E5F-8B08-4C75-8827-4F9A0D4587A4

Q37425231-1EE2391D-F1A5-4B6D-AAD5-7B1459ADF124

Q37425231-6347023D-F24D-46CE-95EC-6049EC197942

Q37425231-B4F4A25A-7449-4FE2-9793-C0FEA6D0D8D7

P2860

Q37425231-01783C65-2719-484F-AF2D-BB8C68853D18

Q37425231-02256E0B-373B-4777-958E-15BA55FC8143

Q37425231-0C8C91E1-8780-4C69-A7CE-D524C322F16C

Q37425231-13DB7E78-0AFF-4387-843B-B6221FE12F3C

Q37425231-1B2F8DA0-7AD3-470F-BB45-BE3B1CCBA637

Q37425231-1EDCDF9D-9841-43C1-81E3-FD9DDF5BBC43

Q37425231-2C78D381-8A62-4B49-90ED-9DA59533B0D3

Q37425231-2CA07843-128C-41CC-BDEB-2B101E6F90C3

Q37425231-368F8785-11E7-465C-9781-AFFB789DD2FA

Q37425231-3B686F25-9342-4217-8978-BDF7EAC22F2D

P304

Q37425231-09AB01DE-5F81-43E4-AB5D-A6347A5D2E98

P31

Q37425231-FDABF1D2-6355-4E90-9CC2-FF093DDE8556

P356

Q37425231-612BBAFC-97F0-43D7-A167-54C05FACF06B

P407

Q37425231-6D92BF72-6B2E-4BDF-85B1-BAE0F173AE23

P433

Q37425231-B3153ECE-C14C-4AAC-BB5F-A2E073D42388

P478

Q37425231-4ACF32AA-33CE-4D70-BCF2-D3158CE59D37

P50

Q37425231-1DD8EA28-0A78-4256-8734-8E97C19700CB

Q37425231-437DF11B-2C9B-422D-96B2-2E942A8859DA

P577

Q37425231-35A8B5A4-BAB2-4C96-AC8E-7DB95684AC3C

P698

Q37425231-9502C98D-3CC1-4008-A311-F28BFD8D88B7

P921

Q37425231-04093B63-0DB9-45B7-A6E0-DE8B616F969F

Q37425231-31288E4B-FBD8-4185-9E49-5380D62D6612

Q37425231-9B919696-FF01-4040-A798-5E3AFD7DD1C2

P932

Q37425231-76D03F13-C411-42F4-A6AA-3DD4B7AA5B85

P356

1673-5374.193242

P1433

Neural Regeneration Research

P1476

Anti-apoptotic effect of Shudi ...... models of Parkinson's disease.

@en

P2093

Jie Zhou

http://www.w3.org/2001/XMLSchema#string

Jing He

http://www.w3.org/2001/XMLSchema#string

Qing Ye

http://www.w3.org/2001/XMLSchema#string

Xiao-Lei Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.

Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody.

Effect of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias.

Pigment epithelium-derived factor (PEDF) protects cortical neurons in vitro from oxidant injury by activation of extracellular signal-regulated kinase (ERK) 1/2 and induction of Bcl-2.

Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.

Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease

L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?

Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.

Reactive oxygen species mediate nitric oxide production through ERK/JNK MAPK signaling in HAPI microglia after PFOS exposure.

P304

1625-1632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/1673-5374.193242

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27904494

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

apoptotic process

substantia nigra

P932

5116842

http://www.w3.org/2001/XMLSchema#string